Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome: Incidence, recognition and management

American Journal of Clinical Dermatology

Volumn 1, Issue 4, 2000, Pages 225-234

  Nagore, Eduardo ^a,c   Insa, Amelia ^b   Sanmartín, Onofre ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; DRUG ERUPTION; HAND DISEASE; HUMAN; INCIDENCE; REVIEW; SKIN DISEASE; SYNDROME;

ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; INCIDENCE; SYNDROME;

EID: 0034231616     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200001040-00004     Document Type: Review

References (102)

1. Zuehlke RK. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 1974; 148 (2): 90-2
2. Komamura H, Higashiyama M, Hashimoto K, et al. Three cases of chemotherapy-induced acral erythema. J Dermatol 1995 Feb; 22 (2): 116-21
3. Amantea M, Newman MS, Sullivan TM, et al. Relationship of dose intensity to the induction of palmar-plantar erythrodysesthesia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 1999 Jan; 18 (1): 17-26
4. Azurdia RM, Clark RE, Friedmann PS. Chemotherapy-induced acral erythema (CIAE) with bullous reaction. Clin Exp Dermatol 1999 Mar; 24 (2): 64-6
5. Ayash LJ, Elias A, Ibrahim J, et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol Mar; 16 (3): 1000-7
6. Baer MR, King LE, Wolff SN. Palmar-plantar erythrodysesthesia and cytarabine. Ann Intern Med 1985 Apr; 102 (4): 556
7. Banfield GK, Crate ID, Griffiths CL. Long-term sequelae of palmar-plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy. J R Soc Med 1995 Jun; 88 (6): 356P-357P
8. Bastida J, Diaz-Cascajo C, Borghi S. Chemotherapy-induced acral erythema due to Tegafur. Acta Derm Venereol 1997 Jan; 77 (1): 72-3
9. Beard JS, Smith KJ, Skelton HG. Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease. J Am Acad Dermatol 1993 Aug; 29 (2 Pt 2): 325-30
10. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel refractory metastatic breast cancer. J Clin Oncol 1999 Feb; 17 (2): 485-93
11. Budd GT, Fleming TR, Bukowsky RM, et al. 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Soutwest Oncology Group study. J Clin Oncol 1987 Feb; 5 (2): 272-7
12. Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998 May; 16 (5): 1795-802
13. Bunnell CA, Winer EP. Oral 5-FU analogues in the treatment of Breast Cancer. Oncology (Huntingt) 1998 Oct; 12 (10 Suppl. 7): 39-43
14. Burgdorf WH, Gilmore WA, Ganick RG. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med 1982 Jul; 97 (1): 61-2
15. Calista D, Landi C. Cytarabine-induced acral erythema: a localized form of toxic epidermal necrolysis? J Eur Acad Dermatol Venereol 1998 May; 10 (3): 274-5
16. Camps C, Soler JJ, Godes MJ, et al. Toxicidad cutánea del ftorafur, síndrome manos-pies o eritrodisestesia palmoplantar. Rev Clin Esp 1991; 188: 165-6
17. Cassidy J, Dirix L, Bissett D, et al. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 1998 Nov; 4 (11): 2755-61
18. Chiara S, Nobile MT, Barzacchi C, et al. Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer 1997; 33 (6): 967-9
19. Cohen PR. Acral erythema: a clinical review. Cutis 1993 Mar; 51 (3): 175-9
20. Comandone A, Bretti S, LaGrotta G, et al. Palmar-plantar erythrodysesthesia syndrome associated with 5-fluorouracil treatment. Anticancer Res 1993; 13: 1781-3
21. Conroy T, Geoffrois L, Guillemin F, et al. Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma. Cancer 1993 Oct 1; 72 (7): 2190-7
22. Cordonnier C, Roujeau JC, Vernant JP, et al. Cancer Chemotherapy and acral erythema. Ann Intern Med 1982; 97: 783
23. Cox GJ, Robertson DB. Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy. Arch Dermatol 1986; 122: 1413-4
24. Crider MK, Jansen J, Norins AL, et al. Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation. Arch Dermatol 1986 Sep; 122 (9): 1023-7
25. Curran CF, Luce JK. Fluorouracil and palmar-plantar erythrodysesthesia. Ann Intern Med 1989 Nov 15; 111 (10): 858
26. De Argila D, Dominguez JD, Iglesias L. Taxol-induced acral erythema. Dermatology 1996; 192 (4): 377-8
27. De Argila Fernández-Durán D, Rivera Díaz R, López Estebaranz JL, et al. Eritema acral inducido por 5-fluorouracilo en infusión contínua. Presentación de un caso y revisión de la literatura. Actas Dermosifiliogr 1993; 84: 315-8
28. De Gramont A, Louvet C, André T, et al. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Eur J Cancer 1998; 34 (5): 619-26
29. Demircay Z, Gurbuz O, Alpdogan TB, et al. Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases. Int J Dermatol 1997 Aug; 36 (8): 593-8
30. Díaz-Rubio E, Aranda E, Martin M, et al. Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. Eur J Cancer 1990; 26; 727-9
31. Doyle LA, Berg C, Bottino G, et al. Erythema and desquamation after high-dose methotrexate. Ann Intern Med 1983; 98: 611-2
32. Ellerhorst JA, Bedikian A, Ring S, et al. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. Oncol Rep 1999 Sep-Oct; 6 (5): 1097-9
33. Fabian CJ, Molina R, Slavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8: 57-63
34. Fariña MC, Andrade J, Soriano ML, et al. Eritema acral inducido por quimioterapia. Descripción de cuatro casos y revisión de la literatura. Actas Dermosifiliogr 1998; 89: 385-91
35. Gabizon A, Catane R, Uziely B. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-92
36. Gabra H, Cameron DA, Lee LE, et al. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. Br J Cancer 1996; 74: 2008-12
37. Gordon KB, Tajuddin A, Guitart J, et al. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995; 75: 2169-73
38. Guillaume JC, Carp E, Rougier P, et al. Effets secondaires cutanéo-muqueux des perfusions continues de 5-fluorouracile: 12 observations. Ann Dermatol Venereol 1988; 115: 1167-9
39. Hellier I, Bessis D, Sotto A, et al. High-dose methotrexate-induced bullous variant of acral erythema. Arch Dermatol 1996 May; 132 (5): 590-1
40. Herzig RH, Wolff SN, Lazarus HM, et al. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62: 361-9
41. Hines JD, Zakem MH, Adelstein TJ, et al. Treatment of advanced stage colorectal adenocarcinoma with fluorouracil and high-dose leucovorin calcium: a pilot study. J Clin Oncol 1988; 6: 142-6
42. Hoff PM, Valero V, Ibrahim N, et al. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 1998 Mar 1; 82 (5): 965-9
43. Ikeda H, Kawano H, Kitaura T, et al. Acral erythema associated with high-dose methotrexate infusion. Ann Pharmacother 1999 May; 33 (5): 646
44. Jucglà A, Sais G, Navarro M, et al. Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur. Arch Dermatol 1995 Mar; 131 (3): 364-5
45. Kampmann KK, Graves T, Rogers SD. Acral erythema secondary to high-dose cytosine arabinoside with pain worsened by cyclosporine infusions. Cancer 1989 Jun 15; 63 (12): 2482-5
46. Koletsky A, Jahanzeb M, Radice P, et al. A randomized phase II trial of pegylated liposomal doxorubicin (PG-LD) as second line treatment in non-small cell lung cancer (NSCLC) patients with prior exposure to platinum based therapy [abstract 1888]. Proc Am Soc Clin Oncol 1998; 17: 490A
47. Kroll SS, Koller CA, Kaled S, et al. Chemotherapy-induced acral erythema: desquamating lesions involving the hands and feet. Ann Plast Surg 1989 Sep; 23 (3): 263-5
48. Krulder JWM, Vlasveld LT, Willemze R. Erythema and swelling of ears after treatment with cytarabine for leukemia. Eur J Cancer 1990; 26: 649-50
49. Leichman CG, Leichman L, Spears CP, et al. Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. J Natl Cancer Inst 1993; 85: 41-4
50. Levine LE, Medenica MM, Lorincz AL, et al. Distinctive acral erythema occurring during therapy for severe myelogenous leukemia. Arch Dermatol 1985 Jan; 121 (1): 102-4
51. Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425-32
52. Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101: 798-800
53. Matsuyama JR, Kwok KK. A variant of the chemotherapy-associated erythrodysesthesia syndrome related to high-dose cyclophosphamide. DICP 1989 Oct; 23 (10): 776,778-9
54. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998 Nov; 16 (11): 3537-41
55. Millot F, Auriol F, Brecheteau P, et al. Acral erythema in children receiving high-dose methotrexate. Pediatr Dermatol 1999 Sep-Oct; 16 (5): 398-400
56. Mortimer JE, Anderson I. Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity. Cancer Chemother Pharmacol 1990; 26: 449-52
57. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractarory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997 Mar; 15 (3): 987-93
58. Murphy CP, Harden EA, Herzig RH. Dose-related cutaneous toxicities with etoposide. Cancer 1993 May 15; 71 (10): 3153-5
59. Nagore E, Sánchez-Motilla JM, Insa A, et al. Síndrome de eritrodisestesia palmo-plantar por 5-fluorouracilo: respuesta favorable al tratamiento con piridoxina. Med Cut I L A 1998; 26: 35-8
60. Ogawa H, Sugiyama H, Tani Y, et al. High incidence of chemotherapy-induced acral erythema in female patients with non-Hodgkin's lymphoma treated with the VACOP-B regimen. Leuk Lymphoma 1998 Mar; 29 (1-2): 171-7
61. Peters WG, Willemze R. Palmar-plantar skin changes and cytarabine. Ann Intern Med 1985; 103: 805
62. Popescu RA, Norman A, Ross PJ, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999 Aug; 17 (8): 2412-8
63. Portal I, Cardenal F, Garcia-del-Muro X. Etoposide-related acral erythema. Cancer Chemother Pharmacol 1994; 34 (2): 181
64. Revenga Arranz F, Fernandez-Duran DA, Grande C, et al. Acute and painful erythema of the hands and feet. Acral erythema induced by chemotherapy. Arch Dermatol 1997 Apr; 133 (4): 499-500, 502-3
65. Rios-Buceta L, Buezo GF, Peñas PF, et al. Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur. Acta Derm Venereol 1997 Jan; 77 (1): 80-1
66. Rongioletti F, Ballestrero A, Bogliolo F, et al. Necrotizing eccrine squamous syringometaplasia presenting as acral erythema. J Cutan Pathol 1991 Dec; 18 (6): 453-6
67. Samuels BL, Vogelzang NJ, Ruane M, et al. Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat Rep 1987 Oct; 71 (10): 971-2
68. Schuster D, Heim ME, Decoster G, et al. Phase I-II trial of doxifluridine (5'DFUR) administered as long-term continuous infusion using a portable infusion pump for advanced colorectal cancer. Eur J Cancer Clin Oncol 1989 Nov; 25 (11): 1543-8
69. Sella A, Kilbourn R, Amato R, et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 1994 Apr; 12 (4): 683-8
70. Shall L, Lucas GS, Whittaker JA, et al. Painful red hands: a side effect of leukaemia therapy. Br J Dermatol 1988; 119: 249-53
71. Silver FS, Espinoza LR, Hartmann RC. Acral erythema and hydroxyurea. Ann Intern Med 1983 May; 98 (5 Pt 1): 675
72. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995 Jul; 13 (7): 1777-85
73. Vakalis D, Ioannides D, Lazaridou E, et al. Acral erythema induced by chemotherapy with cisplatin. Br J Dermatol 1998 Oct; 139 (4): 750-1
74. Vargas-Diez E, Abajo P, Fraga J, et al. Chemotherapy-induced acral erythema. Acta Denn Venereol 1999 Mar; 79 (2): 173-5
75. Villalona-Calero MA, Weiss GR, Burris HA, et al. Phase I and pharmacokynetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol 1999 Jun; 17 (6): 1915-25
76. Waltzer JF, Flowers FP. Bullous variant of chemotherapy-induced acral erythema. Arch Dermatol 1993 Jan; 129 (1): 43-5
77. Weh HJ, Wilke HJ, Dierlamm J, et al. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994; 5: 233-7
78. Whitlock JA, Wells RJ, Hord JD, et al. High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia. Leukemia 1997 Feb; 11 (2): 185-9
79. Zimmerman GC, Keeling JH, Burris HA, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995 Feb; 131 (2): 202-6
80. Perry MC, editor. The chemotherapy source book. 2nd ed. Baltimore, USA: Williams & Wilkins, 1996
81. Vukelja SJ, Lombardo FA, James WD, et al. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1989 Oct 15; 111 (8): 688-9
82. Brown J, Burck K, Black D, et al. Treatment of cytarabine acral erythema with corticosteroids. J Am Acad Dermatol 1991 Jun; 24 (6 Pt 1): 1023-5
83. Titgan MA. Prevention of palmar-plantar erythrodysesthesia associated with liposome-encapsulated doxorubicin (Doxil®) by oral dexamethasone [abstract 288]. Proc Am Soc Clin Oncol 16: 82A, 1997
84. Vail DM, Chun R, Thamm DH, et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998 Jun; 4 (6): 1567-71
85. Lopez AM, Wallace L, Dorr RT, et al. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999; 44 (4): 303-6
86. Vukelja SJ, Baker WJ, Burris III HA. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 1993 Sep 1; 85 (17): 1432-3
87. Zimmerman GC, Keeling JH, Lowry M, et al. Prevention of docetaxel-induced erythrodysesthesia with local hypothermia. J Natl Cancer Inst 1994; 86: 557
88. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40: 367-98
89. Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991 Mar; 24 (3): 457-61
90. Valks R, Fraga J, Porras-Luque J, et al. Chemotherapy-induced eccrine squamous syringometaplasia. A distinctive eruption in patients receiving hematopoietic progenitor cells. Arch Dermatol 1997; 133: 873-8
91. Esteve E, Schillio Y, Vaillant L, et al. Efficacité de la corticothérapie séquentielle dans un cas d'érythème acral douloureux secondaire au 5-fluoro-uracile à fortes doses. Ann Med Interne (Paris) 1995; 146 (3): 192-3
92. Fitzpatrick JE. The cutaneous histopathology of chemotherapeutic reactions. J Cutan Pathol. 1993 Feb; 20 (1): 1-14
93. Sanmartín O, Botella R, Guillén C. Efectos adversos cutáneous de la quimioterapia. Piel 1996 Oct; 11 (8): 406-18
94. Sale GE, Lerner KG, Barker EA, et al. The skin biopsy in the diagnosis of acute graft-versus-host disease of man. Am J Pathol 1977; 89: 621-35
95. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000 Mar; 18 (6): 1337-45
96. Burnstain HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000 Mar; 18 (6): 1212-9
97. Becker KW, Kienecker EW, Dick P. A contribution to the scientific assessment of degenerative and regenerative processes of peripheral nerve fibers following axonotmesis under the systemic administration of vitamins B1, B6 and B12 -light and electron microscopy findings of the saphenous nerve in the rabbit. Neurochirurgia (Stuttg) 1990 Jul; 33 (4): 113-21
98. Shah BR, Santucci K, Sinert R, et al. Acute isoniazid neurotoxicity in an urban hospital. Pediatrics 1995 May; 95 (5): 700-4
99. Nand S, Messmore Jr HL, Patel R, et al. Neurotoxicity associated with systemic high-dose cytosine arabinoside. J Clin Oncol 1986 Apr; 4 (4): 571-5
100. Jackson Jr DV, Pope EK, McMahan RA, et al. Clinical trial of pyridoxine to reduce vincristine neurotoxicity. J Neurooncol 1986; 4 (1): 37-41
101. Wiernik PH, Yeap B, Vogl SE, et al. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest 1992; 10 (1): 1-9
102. Bertelli G, Gozza A, Forno GB, et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995 Nov; 13 (11): 2851-5